PHIL® Liquid Embolic System for Arteriovenous Dural Fistula (PHIL dAVF Trial)

N/A

Waitlist Available

Led By Alan Boulos, MD

Research Sponsored by Microvention-Terumo, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3-6 month follow-up

Awards & highlights

PHIL dAVF Trial Summary

This trial is testing a new treatment for dural AVFs, which are abnormal connections between arteries and veins in the brain. The new treatment involves injecting a liquid into the AVF to block it off.

Eligible Conditions

Arteriovenous Dural Fistula

PHIL dAVF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3-6 month follow-up

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3-6 month follow-up

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-6 month follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Subjects with neurological death or ipsilateral stroke

Secondary outcome measures

Device-related adverse events

Technical events during the PHIL embolization procedure(s)

PHIL dAVF Trial Design

1Treatment groups

Experimental Treatment

Group I: dAVF treatmentExperimental Treatment1 Intervention

PHIL® Liquid Embolic System

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Microvention-Terumo, Inc.Lead Sponsor

29 Previous Clinical Trials

6,206 Total Patients Enrolled

Alan Boulos, MDPrincipal InvestigatorAlbany Medical College

J Mocco, MDPrincipal InvestigatorMt. Sinai

4 Previous Clinical Trials

1,275 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I satisfy the prerequisites for entering into this experiment?

"Inclusion criteria for the trial is an arteriovenous dural fistula and aged between 22-80. At this time, 75 patients have been approved to partake in the experiment."

Answered by AI

Is enrollment open for this clinical trial?

"This investigation, which was initially publicised on August 24th 2018 and lastly amended on February 8th 2022, is not currently accepting participants according to clinicaltrials.gov's records. Nonetheless, there are 110 other trials open for recruitment at the moment."

Answered by AI